45.86MMarket Cap-1057P/E (TTM)
1.470High1.365Low277.25KVolume1.410Open1.390Pre Close395.87KTurnover0.89%Turnover RatioLossP/E (Static)31.20MShares10.24052wk High1.20P/B45.63MFloat Cap1.33052wk Low--Dividend TTM31.04MShs Float450.000Historical High--Div YieldTTM7.55%Amplitude1.330Historical Low1.427Avg Price1Lot Size
Actinium Stock Forum
PR Newswire· 10 mins ago
SK Biopharmaceuticals, Korea Institute of Radiological and Medical Sciences collaborate on discovering and developing radiopharmaceutical drug candidates using an alpha-particleemittingradioisotope, actinium-225, for potential cancer treatm...
Actinium Announces Publication Of Phase 3 SIERRA Results Of Iomab-B - Quick Facts
Good lesson on the higher risks of biologics though. BLA (biologics license application) a relatively new classification (maybe 5 or so years?) meant to divert biologics from the NDA process that small molecule drugs go through.
In practical terms,...
Actinium Pharmaceuticals Inc - Iomab-B Well Tolerated in Older Relapsed/Refractory Aml Patients
September 05, 2024 08:00 AM Eastern Daylight Time!!! From this morning! BUT THIS ONE BELOW JUST WAS RELEASED VIA SEEKING ALPHA! NOT SURE IF THEY ARE MISPRINT OF DRUG? OR ANOTHER APPROVAL?
Perspective gets FDA fast track status for radiopharmaceutical VMT101
No comment yet